+34 620 10 75 37info@nanbiosis.com

Posts on Jan 1970

You are here : Home / 2025 / December

Ready your proposals: Open Call starts on january

NANBIOSIS opens in January the 1st Competitive Open Call of 2026 for our “Cutting-Edge Biomedical Solutions” and services.

Last year we made two Open Calls, and it was about time to introduce you to the first call of 2026: offering you our discounts and preferential access during the entire month of January!

Our publicly funded facilities and internationally renowned scientists will help you design and test biomedical solutions to your heart’s content. We are open to all interested national and international users who may come either from the public or the private sector. You can apply to use our services in two modalities: under the “Competitive Open Access” (within our two designated yearly calls) or by “Access on Demand”, your choice.

To make that happen, at least 20% of the capacity of the Units of NANBIOSIS is offered on the Competitive Open Access modality. The proposals granted under this modality will be prioritized according to criteria of scientific and technical quality and singularity. In addition, a 5% discount will be applied for those proposals that resort to at least one of our integrated services, the Cutting-Edge Biomedical Solutions.

NANBIOSIS is a research infrastructure for Biomedicine included in the the Spanish Map of ICTS (Spanish for “Scientific and Technical Unique Infrastructures”), approved by the Spanish Ministerio de Ciencia, Innovación y Universidades.

There are 2 calls per year for Competitive Open Access that allow the prioritization of the best proposals. Click here to apply.

As stated, the next call will open on January 2026. The applications can be submitted throughout the whole month (due date January 31th). Access application forms submitted after that date will be processed under the “Access on Demand” modality.

Proposals granted in the Competitive Open Access modality must meet, at least, one of the circumstances listed in the access application form (“order request“), in order to demonstrate their scientific and technical quality or singularity.

Thus, for example, applications related to R&D projects funded through national or European calls are eligible. In addition, the proposals are required to use one of the NANBIOSIS “Cutting-Edge Biomedical Solutions”. That implies the interaction of at least two of our Units. The choice of said Units can be modified to your specific needs.

Mark your calendar and ready your proposals! The Call will be open until the end of January 2026.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS Revalidated as a Unique Scientific and Technical Infrastructure (ICTS) in Spain

NANBIOSIS has been revalidated as a Spanish ICTS in November 2025, reaffirming its strategic role in cutting-edge biomedical research and innovation.

Valencia, November 2025 — Last month, the Government of Spain reaffirmed NANBIOSIS as an Infraestructura Científico-Técnica Singular (ICTS), confirming its status as a key national infrastructure supporting cutting-edge research, technological development, and innovation in biomedicine and nanotechnology.

The ICTS designation is granted to publicly owned scientific and technical infrastructures that are unique or exceptional, require high investment and operational resources, and provide open and competitive access to the entire R&D&I community. These infrastructures play a strategic role in enabling frontier research, facilitating knowledge generation and preservation, promoting technology transfer, and fostering innovation.

ICTS are distributed throughout Spain and are included in the Map of Unique Scientific and Technical Infrastructures, a dynamic framework that ensures infrastructures continuously meet strict excellence, accessibility, and quality requirements. Depending on their level of integration, ICTS may operate as single-site facilities, networks of infrastructures, or distributed infrastructures.

The revalidation of NANBIOSIS as an ICTS highlights its sustained scientific excellence, public-service mission, and strategic relevance within the Spanish research ecosystem. This recognition reinforces the commitment of NANBIOSIS to offering advanced services and state-of-the-art capabilities to academic researchers, healthcare institutions, and industrial partners.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS U26 Contributes to New Study Using CMR and PET to Track Myocardial Infarction Progression in Mice

Multimodal CMR/PET imaging reveals key differences in infarct evolution in mice. NANBIOSIS U26 contributed technical expertise and advanced imaging support.

Valencia, December 2025 — A new scientific publication, “Characterization of Infarct Size and Remodeling Using CMR and PET in Mice Models of Reperfused and Non-Reperfused Myocardial Infarction” (Diagnostics, 2025), highlights the value of combining cardiovascular magnetic resonance (CMR) and positron emission tomography (PET) for non-invasive, longitudinal evaluation of heart damage in preclinical models of myocardial infarction. The study features the participation of NANBIOSIS Unit 26, which contributed both technical expertise and advanced imaging infrastructure.

A multimodal approach to understanding Heart Injury

The research compares two experimental mouse models of myocardial infarction—one with permanent coronary occlusion (non-reperfused) and another with transient occlusion followed by reperfusion. Using CMR and fluorine-18 FDG PET imaging at baseline and at 1, 7, and 21 days after infarction, the authors assessed:

  • Infarct size
  • Systolic function
  • Myocardial glucose metabolism

Masson’s trichrome histology served as the reference standard for infarct size at the chronic phase.

The results showed that both models exhibited infarction, reduced systolic function, and decreased glucose metabolism as early as 24 hours post-event. By day 21, reperfused mice demonstrated smaller infarcts and better-preserved cardiac function, although metabolic activity measured by PET did not differ significantly between groups. Moreover, early CMR and PET measurements proved to be strong predictors of long-term outcomes.

These findings underscore the value of combined PET/CMR imaging for monitoring disease progression and evaluating new therapeutic strategies in preclinical cardiovascular research.

NANBIOSIS Participation

NANBIOSIS Unit 26 (NMR Biomedical Applications II) played an essential role in the project by providing both expert technical support—via technician and co-author Mustafa Ezzeddin—and access to its specialized imaging facilities.

“To continue advancing the Biomedical and Metabolomics Imaging section, we are pleased to share that we have published an article using a murine model of acute myocardial infarction, employing 3T MRI and PET-CLIP-ON techniques.”

—Mustafa Ezzeddin, technician at Unit 26 of NANBIOSIS

About NANBIOSIS Unit 26

Located at the Faculty of Medicine of the University of Valencia (UV), Unit 26 offers advanced NMR-based metabolomic and imaging capabilities, including a 14T NMR system for biofluid, cell line, and tissue metabolic profiling. The Unit is coordinated by Dr. Ramón Martínez-Máñez, Principal Investigator of the Applied Molecular Chemistry Group at the Universitat Politècnica de València and Scientific Director of NANBIOSIS, together with Dr. Salvador Gil, Director of the Central Service for Experimental Research (SCSIE).

Reference: DOI

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS showcases its capabilities at Big Science Industry Forum Spain 2025

NANBIOSIS joined BSIFS2025, presenting its ICTS capabilities and strengthening collaboration with national and international Big Science infrastructures.

Madrid, December 2025 — Last week, NANBIOSIS participated in the Big Science Industry Forum Spain 2025 (BSIFS2025), the first national forum designed to strengthen Spain’s Big Science industry and promote collaboration between research infrastructures, companies, and scientific institutions. The event—organised by CDTI Innovation, INDUCIENCIA, and INEUSTAR—highlighted Spain’s technological leadership and its role in major international scientific projects.

Held over two days, BSIFS2025 gathered representatives from leading global research infrastructures in particle physics, fusion, and astronomy, including CERN, ITER and F4E, and ESO, alongside key national ICTS facilities. The forum offered a comprehensive programme featuring procurement updates, technological trends, networking spaces, company exhibitions, and a poster area showcasing research capabilities.

NANBIOSIS was present within the ICTS stand of the Ministry of Science, Innovation and Universities, which received a visit from the Minister, Diana Morant. The infrastructure also presented a poster detailing its services and technological capacities in biomedical research and nanomedicine.

Throughout the event, NANBIOSIS engaged with industry representatives, research centres, and other large scientific facilities, strengthening partnerships and exploring new opportunities for collaboration. Participation in BSIFS2025 reinforced the key role of NANBIOSIS within Spain’s scientific ecosystem and its contributions to innovation, technology transfer, and advanced research services.

NANBIOSIS at BSIFS2025

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS showcases its capabilities at the II Conference on Major Research Infrastructures of CSIC

NANBIOSIS-ICTS participated in the II CSIC Conference on Major Research Infrastructures, presenting its capabilities and services for biomedical research.

Madrid, December 2025 — Just yesterday, 2 of December 2025, NANBIOSIS-ICTS participated in the II Jornada de Grandes Infraestructuras de Investigación del CSIC, a key annual event organised by the Spanish National Research Council (CSIC) at its central headquarters in Madrid. The meeting, held entirely in person, followed the successful first edition in 2024 and aimed to highlight the latest developments, strategic priorities, and services offered by Spain’s Large Scientific and Technological Infrastructures.

The event opened with an institutional welcome from José María Martell (VICYT-CSIC) in representation of Eloísa del Pino, President of CSIC. This was followed by an update on European policies for research infrastructures and a detailed overview presented by José María Martell himself, who outlined the current mapping and diagnostic status of CSIC’s technological infrastructures.

A central roundtable addressed challenges and opportunities for technological infrastructures, moderated by Javier Menéndez González (VAPC-CSIC, ESFRI Chair Office), featuring representatives from CSIC, CDTI, Helmholtz, INTA-CSIC, and CIB-CSIC. The debate highlighted the importance of collaboration, innovation, and strategic alignment between major facilities.

One of the main sessions of the programme focused on presenting several large research infrastructures in which CSIC participates. During this session, NANBIOSIS-ICTS was introduced by Gabriel Alfranca (CIBER-BBN, Communication Manager of NANBIOSIS), who presented the infrastructure’s unique capabilities, advanced biomedical services, and collaboration opportunities for researchers and companies. The session also featured presentations from the Animal Health Research Centre (CISA, INIA-CSIC), AnaEE ERIC, and eLTER, illustrating the breadth of CSIC’s involvement in national and European infrastructures.

The afternoon programme concentrated on data management and open science within major research infrastructures, under the theme “EOSC at CSIC”. Led by Carmen García (IFIC-CSIC), the panel explored strategies for data governance, FAIR principles, and the impact of open data through examples from SKA, EPOS, and Doñana ICTS (LifeWatch ERIC), sparking a vibrant debate on the future of data management and analysis, including the role and challenges of AI usage.

The conference concluded with an open debate and networking session, reinforcing the importance of cooperation between research infrastructures to strengthen Spain’s scientific competitiveness. Through its active participation, NANBIOSIS reasserted its commitment to supporting biomedical research and enabling innovation through high-quality scientific and technological services.

NANBIOSIS at II Jornada de Grandes Infraestructuras de Investigación del CSIC

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More